The Sodium Phosphocreatine's Effect On Dilated Cardiomyopathy Patients With Heart Failure

ObjectiveBy observing the effect of the treatment using sodium Phosphocreatine on dilated cardiomyopathy patients with heart failure to explore its possible mechanisms and evaluate its clinical value. Indicators were the changes in left ventricular function and cardiac functional classification.MethodsThe 103 cases of dilated cardiomyopathy with heart failure were randomized into two groups, control group was given ACEI or AEB agents, diuretics,βblockers (without contraindications), cardiac stimulant, vasodilator agent-based anti-cardiac insufficiency treatment, the therapy group was given both the routine treatment and Sodium Phosphocreatine. Took an observation before and after treatment in patients on the changes in heart functional classification, left ventricular diastolic function parameters, and accessed the adverse drug reactions.ResultThe clinical symptoms of the two groups has improved after treatment, but the clinical symptoms and signs of the therapy group such as shortness of breath, palpitations, edema etc. were improved more than the control group(P<0.05). The overall improvement of cardiac function in the effective rate were higher (P<0.05), the decrease in pro-brain natriuretic peptide (BNP) levels, the increase in left ventricular ejection scores were obviously (P<0.05). And no adverse reactions.ConclusionSodium Phosphocreatine can safely and effectively improve the clinical symptoms and cardiac function in dilated cardiomyopathy patients with cardiac insufficiency.